Flubendazole also interferes with STAT3 activity, as well as with the function/differentiation of T helper (Th)-17 cells and regulatory T-cells, thus, sustaining an antitumor response in triple-negative breast cancer (TNBC) [46], CRC [45], and non-small-cell lung cancer (NSCLC) [47]. This evidence concerns the gene STAT3 and non-small cell lung carcinoma.